NASDAQ:APTXAptinyx Stock Price, Forecast & News

Aptinyx's stock was trading at $2.43 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, APTX stock has increased by 72.8% and is now trading at $4.20. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptinyx in the last year. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aptinyx.

Aptinyx is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Aptinyx.

Aptinyx Inc (NASDAQ:APTX) announced its quarterly earnings results on Thursday, May, 14th. The company reported ($0.34) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.33) by $0.01. The business had revenue of $0.82 million for the quarter, compared to the consensus estimate of $0.91 million. Aptinyx had a negative return on equity of 47.99% and a negative net margin of 1,540.42%. View Aptinyx's earnings history.

6 brokerages have issued 1-year price objectives for Aptinyx's stock. Their forecasts range from $7.00 to $12.00. On average, they expect Aptinyx's stock price to reach $8.67 in the next year. This suggests a possible upside of 106.3% from the stock's current price. View analysts' price targets for Aptinyx.

Media headlines about APTX stock have been trending neutral recently, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Aptinyx earned a media sentiment score of 0.1 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutAptinyx.

Some companies that are related to Aptinyx include Kura Oncology (KURA), Kadmon (KDMN), Molecular Templates (MTEM), ZIOPHARM Oncology (ZIOP), Eagle Pharmaceuticals (EGRX), Retrophin (RTRX), Kala Pharmaceuticals (KALA), Homology Medicines (FIXX), Nabriva Therapeutics (NBRV), Ardelyx (ARDX), Akero Therapeutics (AKRO), Assembly Biosciences (ASMB), G1 Therapeutics (GTHX), Morphic (MORF) and Sinovac Biotech (SVA). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptinyx investors own include Onconova Therapeutics (ONTX), Opko Health (OPK), VBI Vaccines (VBIV), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), ADMA Biologics (ADMA), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), Square (SQ) and vTv Therapeutics (VTVT).

(APTX) raised $77 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 5,300,000 shares at $14.00-$15.00 per share. J.P. Morgan, Cowen, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

Aptinyx trades on the NASDAQ under the ticker symbol "APTX."

Aptinyx's stock is owned by many different retail and institutional investors. Top institutional shareholders include Orbimed Advisors LLC (2.55%), Ikarian Capital LLC (1.30%), BlackRock Inc. (0.94%), Sphera Funds Management LTD. (0.90%), Geode Capital Management LLC (0.45%) and JPMorgan Chase & Co. (0.45%). Company insiders that own Aptinyx stock include Adam Koppel, Adams Street Partners Llc, Andrew Kidd, Ashish Khanna, Henry O Gosebruch, Norbert G Riedel, Rachel E Sherman, Robert J Hombach and Torsten M Madsen. View institutional ownership trends for Aptinyx.

APTX stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, and Squarepoint Ops LLC. View insider buying and selling activity for Aptinyx.

APTX stock was purchased by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Ikarian Capital LLC, Sphera Funds Management LTD., Geode Capital Management LLC, Acadian Asset Management LLC, BlackRock Inc., JPMorgan Chase & Co., and Bank of New York Mellon Corp. Company insiders that have bought Aptinyx stock in the last two years include Adam Koppel, Adams Street Partners Llc, Andrew Kidd, Ashish Khanna, Henry O Gosebruch, Norbert G Riedel, Rachel E Sherman, Robert J Hombach, and Torsten M Madsen. View insider buying and selling activity for Aptinyx.

Shares of APTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of APTX stock can currently be purchased for approximately $4.20.

Aptinyx has a market capitalization of $191.77 million and generates $3.67 million in revenue each year. The company earns $-57,410,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis.

The official website for Aptinyx is www.aptinyx.com.

Aptinyx's mailing address is 909 DAVIS STREET SUITE 600, EVANSTON IL, 60201. The company can be reached via phone at 847-871-0377 or via email at [email protected]